A practical guide to Bayesian group sequential designs

被引:53
|
作者
Gsponer, Thomas [1 ]
Gerber, Florian [1 ]
Bornkamp, Bjoern [2 ]
Ohlssen, David [3 ]
Vandemeulebroecke, Marc [4 ]
Schmidli, Heinz [2 ]
机构
[1] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland
[2] Novartis Pharma AG, Stat Methodol, CH-4002 Basel, Switzerland
[3] Novartis Pharmaceut, Stat Methodol, E Hanover, NJ USA
[4] Novartis Pharma AG, Integrated Informat Sci, CH-4002 Basel, Switzerland
关键词
ENHANCING LESION COUNTS; CLINICAL-TRIAL; MULTIPLE-SCLEROSIS; IMPORTANT DIFFERENCE; SAMPLE-SIZE; DECISION; INFORMATION; CRITERION; POINT; MODEL;
D O I
10.1002/pst.1593
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Bayesian approaches to the monitoring of group sequential designs have two main advantages compared with classical group sequential designs: first, they facilitate implementation of interim success and futility criteria that are tailored to the subsequent decision making, and second, they allow inclusion of prior information on the treatment difference and on the control group. A general class of Bayesian group sequential designs is presented, where multiple criteria based on the posterior distribution can be defined to reflect clinically meaningful decision criteria on whether to stop or continue the trial at the interim analyses. To evaluate the frequentist operating characteristics of these designs, both simulation methods and numerical integration methods are proposed, as implemented in the corresponding R package gsbDesign. Normal approximations are used to allow fast calculation of these characteristics for various endpoints. The practical implementation of the approach is illustrated with several clinical trial examples from different phases of drug development, with various endpoints, and informative priors. Copyright © 2013 John Wiley & Sons, Ltd.
引用
收藏
页码:71 / 80
页数:10
相关论文
共 50 条
  • [1] Bayesian evaluation of group sequential clinical trial designs
    Emerson, Scott S.
    Kittelson, John M.
    Gillen, Daniel L.
    [J]. STATISTICS IN MEDICINE, 2007, 26 (07) : 1431 - 1449
  • [2] A practical comparison of group-sequential and adaptive designs
    Kelly, PJ
    Sooriyarachchi, MR
    Stallard, N
    Todd, S
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2005, 15 (04) : 719 - 738
  • [3] Bayesian group sequential designs for cluster-randomized trials
    Shen, Junwei
    Golchi, Shirin
    Moodie, Erica E. M.
    Benrimoh, David
    [J]. STAT, 2022, 11 (01):
  • [4] Comparison of Bayesian and frequentist group-sequential clinical trial designs
    Nigel Stallard
    Susan Todd
    Elizabeth G. Ryan
    Simon Gates
    [J]. BMC Medical Research Methodology, 20
  • [5] Control of type I error rates in Bayesian group sequential designs
    Shi, Haolun
    Yin, Guosheng
    [J]. TRIALS, 2017, 18
  • [6] Comparison of Bayesian and frequentist group-sequential clinical trial designs
    Stallard, Nigel
    Todd, Susan
    Ryan, Elizabeth G.
    Gates, Simon
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2020, 20 (01)
  • [7] Bayesian sequential designs in studies with multilevel data
    Moerbeek, Mirjam
    [J]. BEHAVIOR RESEARCH METHODS, 2024, 56 (06) : 5849 - 5861
  • [8] GROUP SEQUENTIAL CLINICAL-TRIALS - A CLASSICAL EVALUATION OF BAYESIAN DECISION-THEORETIC DESIGNS
    LEWIS, RJ
    BERRY, DA
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1994, 89 (428) : 1528 - 1534
  • [9] Probability of success and group sequential designs
    Grieve, Andrew P.
    [J]. PHARMACEUTICAL STATISTICS, 2024, 23 (02) : 185 - 203
  • [10] DESIGNS FOR GROUP SEQUENTIAL-TESTS
    FLEMING, TR
    HARRINGTON, DP
    OBRIEN, PC
    [J]. CONTROLLED CLINICAL TRIALS, 1984, 5 (04): : 348 - 361